Holen Sie sich die Stockscreener-App
4.87
0.41%
-0.02
Annovis Bio Inc Aktie (ANVS) Neueste Nachrichten
Annovis Bio Announces Public Offering of Common Stock and Warrants - MyChesCo
Major Funding Push: Annovis Bio's Next Move in Revolutionary Alzheimer's Treatment Race - StockTitan
Annovis Bio, Inc. Announces Proposed Public Offering - The Bakersfield Californian
Annovis Bio Secures U.S. Patent for Neuroprotective Drug Buntanetap - MSN
What's Going With Annovis Bio Shares Tuesday? - MSN
Why Intuitive Surgical Stock Was Pulling Back Today - The Globe and Mail
Merit Financial Group LLC Has $496,000 Holdings in Annovis Bio, Inc. (NYSE:ANVS) - MarketBeat
Parkinson's Disease Clinical and Non-Clinical Studies, Key - openPR
Annovis Bio granted U.S. patent covering buntanetap - Yahoo Finance
Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection - GlobeNewswire
Annovis Bio secures US patent for brain injury treatment By Investing.com - Investing.com Nigeria
Annovis Bio secures US patent for brain injury treatment - Investing.com India
Annovis Bio Secures Key U.S. Patent for Brain Injury Treatment Breakthrough Buntanetap - StockTitan
Passage Bio Reports Promising Data in Trial for Frontotemporal Dementia Treatment - MyChesCo
Geode Capital Management LLC Has $799,000 Position in Annovis Bio, Inc. (NYSE:ANVS) - Defense World
Annovis Bio, Inc. (NYSE:ANVS) Receives $31.40 Average Price Target from Analysts - MarketBeat
Annovis Bio Stock Among Retail's Top Draws After FDA Nod For Final Phase 3 Alzheimer’s Study Protocol - MSN
FDA accepts Annovis’ updated protocol for drug study - Pennsylvania Business Report
FDA Accepts Revised Protocol for Annovis Bio’s Phase 3 Alzheimer’s Study - MSN
FDA approves Annovis Bio's updated Alzheimer's trial protocol By Investing.com - Investing.com Canada
FDA approves Annovis Bio's revised Phase 3 AD study protocol By Investing.com - Investing.com Canada
Annovis Bio stock slips after Alzheimer’s update (ANVS:NYSE) - Seeking Alpha
Annovis Bio, Inc. Announces FDA Accepts Final Protocol for Pivotal Phase 3 Alzheimer?s Disease Study, Streamlining Development Pathway - Marketscreener.com
FDA approves Annovis Bio's updated Alzheimer's trial protocol - Investing.com
FDA approves Annovis Bio's revised Phase 3 AD study protocol - Investing.com
FDA Accepts Final Protocol for Pivotal Phase 3 Alzheimer’s Disease Study, Streamlining Development Pathway - GlobeNewswire
Annovis Bio Streamlines Phase 3 Alzheimer's Trial After FDA Approval, Accelerates Path to Market - StockTitan
State Street Corp Increases Stock Holdings in Annovis Bio, Inc. (NYSE:ANVS) - Defense World
How To Trade (ANVS) - Stock Traders Daily
Annovis Bio Inc (ANVS-N) QuotePress Release - The Globe and Mail
Annovis Bio (NYSE: ANVS) Eyes Opportunities Beyond ‘Year Of Significant Progress’ - Barchart
Annovis Bio (NYSE: ANVS) Committed To Ensuring Highest Standards In Buntanetap Trials - Barchart
Annovis Bio stock hits 52-week low at $4.52 amid market challenges - Investing.com Canada
When (ANVS) Moves Investors should Listen - Stock Traders Daily
Annovis Bio (NYSE: ANVS) Eyes Clear Path Forward For Buntanetap - Barchart
Annovis Bio, Inc. (NYSE:ANVS) Short Interest Update - MarketBeat
Royal Bank of Canada (RY-N) QuotePress Release - The Globe and Mail
Annovis Bio, Inc. (NYSE:ANVS) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Annovis Bio (NYSE: ANVS) Showcases 2024 Achievements and Strategic Vision in Investor Webcast - Barchart
Annovis Bio, Inc. Appoints William Fricker to Serve as Chief Financial Officer on an Interim Basis - Marketscreener.com
Annovis Bio Announces Investor Webcast to Share Key Updates - MSN
Annovis Bio Advances Alzheimer’s and Parkinson’s Drug Trials - TipRanks
Form 424B5 Annovis Bio, Inc. - StreetInsider.com
Annovis Bio appoints interim CFO By Investing.com - Investing.com Nigeria
7 Most Promising Drugs in Parkinson’s Disease Treatment Pipeline - BioSpace
3.95%
2.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):